Use of programmed cell death protein 1 (PD-1) inhibitor therapy in HIV-infected patients with advanced cancer: a single-center study from China

Abstract Background Anti-PD-1 antibodies have been approved for treating several cancer. However, data regarding the safety and efficacy of these agents in HIV-infected patients with cancer is lacking, because these patients are frequently omitted from clinical trials. Objectives The primary aim of...

Повний опис

Бібліографічні деталі

Автори:	Luling Wu, Jie Su, Junyang Yang, Ling Gu, Renfang Zhang, Li Liu, Hongzhou Lu, Jun Chen
Формат:	Artigo
Мова:	Inglês
Опубліковано:	BMC 2023-05-01
Серія:	Infectious Agents and Cancer
Предмети:	HIV Cancer PD-1 ICIs Safety and outcomes
Онлайн доступ:	https://doi.org/10.1186/s13027-023-00512-z
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!